| |||||||
iCell Cardiomyocytes — highly purified in the quantities you need.
Applications include targeted drug discovery, toxicity testing, and other life science research…
Check us out at SOT 2010!
Free CDI & Promega Sponsored Workshop
SOT Workshop with Roche & CDI: Toxicology in the 21st Century - Stem Cells
in Drug Discovery and Development
Learn more about iPS 2.0™: CDI's induced, pluripotent stem (iPS) stem cell technology that coaxes the full potential from adult tissue or blood cells to generate a range of unique, terminally differentiated cells lines for in vitro research and drug discovery applications.
February 8, 2010
Drug Discovery News: Cellular Dynamics Launches Human iPSC-derived Cardiomyocytes
January 22, 2010
MIT Technology Review: Made-to-Order Heart Cells
January 2010
Nature Methods:
IPSCs: One Cell to Rule Them All?
December 16, 2009
Cellular Dynamics Announces Commercial Launch of iCell™ Cardiomyocytes for Drug Candidate Toxicity Screening
November 3, 2009
Large-Scale Production of Human iPS Cell-Derived Cardiomyocytes
– Workshop at the American College of Toxicology (ACT) Annual Meeting,
Cellular Dynamics is the world’s largest producer of fully functional human cells derived from induced pluripotent stem (iPS) cells. In an industry approximately 13 years old, CDI scientists tout more than 275 years combined of stem cell experience. Building on this expertise, our iCell™ products provide industrialized quantities of genetically diverse, terminally differentiated human cells enabling basic research, efficient drug discovery programs, and reliably predictive toxicity and efficacy screening through in vitro clinical trials.